Immunobiology of the sentinel lymph node and its potential role for antitumour immunity

Lancet Oncology

Volumn 7, Issue 12, 2006, Pages 1006-1016

  Kim, Ryungsa ^a   Emi, Manabu ^a   Tanabe, Kazuaki ^a   Arihiro, Koji ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CPG 7909; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MELANOMA VACCINE; MOLGRAMOSTIN; PF 3512676; TOLL LIKE RECEPTOR 9; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LYMPHADENECTOMY; LYMPHOID ORGAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR VOLUME;

HUMANS; IMMUNITY; LYMPH NODES; NEOPLASMS; SENTINEL LYMPH NODE BIOPSY;

EID: 33751333928     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70975-5     Document Type: Review

References (81)

1. Morton D., Wen D., Wong J., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 (1992) 392-399
2. Mamounas E., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 (2005) 2694-2702
3. Pulte D., Li E., Crawford B., et al. Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma. Cancer 104 (2005) 1453-1461
4. Rubello D., Pelizzo M., Al-Nahhas A., et al. The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol (2006). published online April 15. DOI: 10.1016/j.ejso.2006.03.018
5. Lamb P., Griffin S., Burt A., et al. Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. Br J Surg 92 (2005) 60-67
6. Arnould L., Gelly M., Penault-Llorca F., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 94 (2006) 259-267
7. Murta E., Andrade J., Falcao R., and Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumouri 86 (2000) 403-407
8. Matsuura K., Yamaguchi Y., Ueno H., et al. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106 (2006) 1227-1236
9. Yazdi A., Morstedt K., Puchta U., et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol 126 (2005) 393-398
10. Straten P., Dahl C., Schrama D., et al. Identification of identical TCRs in primary melanoma lesions and tumour free corresponding sentinel lymph nodes. Cancer Immunol Immunother 55 (2006) 495-502
11. Marits P., Karlsson M., Dahl K., et al. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 94 (2006) 1478-1484
12. Heath W., and Carbone F. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19 (2001) 47-64
13. Jones C., Cose S., Coles R., et al. Herpes simplex virus type 1-specific cytotoxic T-lymphocyte arming occurs within lymph nodes draining the site of cutaneous infection. J Virol 74 (2000) 2414-2419
14. Flynn K., Belz G., Altman J., et al. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8 (1998) 683-691
15. Wolkers M., Stoetter G., Vyth-Dreese F., and Schumacher T. Redundancy of direct priming and cross-priming in tumour-specific CD8+ T cell responses. J Immunol 167 (2001) 3577-3584
16. Kirk C., Hartigan-O'Connor D., and Mule J. The dynamics of the T-cell antitumour response: chemokine-secreting dendritic cells can prime tumour-reactive T cells extranodally. Cancer Res 61 (2001) 8794-8802
17. Burnet F. The concept of immunological surveillance. Prog Exp Tumour Res 13 (1970) 1-27
18. Itano A., and Jenkins M. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 4 (2003) 733-739
19. Letessier E., Heo D., Okarma T., et al. Enrichment in tumour-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer. Cancer Res 51 (1991) 3891-3899
20. Diederichsen A., Hjelmborg J., Christensen P., et al. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 52 (2003) 423-428
21. Haanen J., Baars A., Gomez R., et al. Melanoma-specific tumour-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55 (2006) 451-458
22. Panelli M., Riker A., Kammula U., et al. Expansion of tumour-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 164 (2000) 495-504
23. Hom S., Rosenberg S., and Topalian S. Specific immune recognition of autologous tumour by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 36 (1993) 1-8
24. Nakagomi H., Petersson M., Magnusson H., et al. Decreased expression of the signal-transducing zeta chains in tumour-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53 (1993) 5610-5612
25. Kurt R., Urba W., Smith J., and Schoof D. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 78 (1998) 16-20
26. Maccalli C., Pisarra P., Vegetti C., et al. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 163 (1999) 6912-6923
27. Kadison A., and Morton D. Immunotherapy of malignant melanoma. Surg Clin North Am 83 (2003) 343-370
28. Caux C., Dezutter-Dambuyant C., Schmitt D., and Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360 (1992) 258-261
29. Molenkamp B., Vuylsteke R., van Leeuwen P., et al. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol 167 (2005) 1301-1307
30. Essner R., and Kojima M. Surgical and molecular approaches to the sentinel lymph nodes. Ann Surg Oncol 8 (2001) 31S-34S
31. Botella-Estrada R., Dasi F., Ramos D., et al. Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res 15 (2005) 99-106
32. Leong S., Peng M., Zhou Y., et al. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 9 (2002) 82-87
33. Lee J., Torisu-Itakara H., Cochran A., et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11 (2005) 107-112
34. Munn D., Sharma M., Lee J., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 (2002) 1867-1870
35. Cochran A., Morton D., Stern S., et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumour biology and treatment. Mod Pathol 14 (2001) 604-608
36. Huang R., Wen D., Guo J., et al. Selective Modulation of Paracortical Dendritic Cells and T-Lymphocytes in Breast Cancer Sentinel Lymph Nodes. Breast J 6 (2000) 225-232
37. Poindexter N., Sahin A., Hunt K., and Grimm E. Analysis of dendritic cells in tumour-free and tumour-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6 (2004) R408-R415
38. Kohrt H., Nouri N., Nowels K., et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2 (2005) e284
39. Schule J., Bergkvist L., Hakansson L., et al. Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat 74 (2002) 33-40
40. Schule J., Bergkvist L., Hakansson L., et al. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J Transl Med 2 (2004) 45
41. Ito M., Minamiya Y., Kawai H., et al. Tumour-Derived TGFbeta-1 Induces Dendritic Cell Apoptosis in the Sentinel Lymph Node. J Immunol 176 (2006) 5637-5643
42. Sakakura K., Chikamatsu K., Sakurai T., et al. Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer. Oral Oncol 41 (2005) 89-96
43. Ishigami S., Natsugoe S., Uenosono Y., et al. Infiltration of antitumour immunocytes into the sentinel node in gastric cancer. J Gastrointest Surg 7 (2003) 735-739
44. Whiteside T. Immune responses to malignancies. J Allergy Clin Immunol 111 (2003) S677-S686
45. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
46. Liu H., Rhodes M., Wiest D., and Vignali D. On the dynamics of TCR: CD3 complex cell surface expression and downmodulation. Immunity 13 (2000) 665-675
47. Boussiotis V., Barber D., Lee B., et al. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 184 (1996) 365-376
48. de Jong E., Smits H., and Kapsenberg M. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 26 (2005) 289-307
49. Dunn G., Bruce A., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 3 (2002) 991-998
50. Gabrilovich D., Ishida T., Oyama T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
51. Kusmartsev S., and Gabrilovich D. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51 (2002) 293-298
52. Zou W., Machelon V., Coulomb-L'Hermin A., et al. Stromal-derived factor-1 in human tumours recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7 (2001) 1339-1346
53. Morelli A. The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant 6 (2006) 254-261
54. Huynh M., Fadok V., and Henson P. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109 (2002) 41-50
55. Morelli A., Larregina A., Shufesky W., et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 101 (2003) 611-620
56. Leong S., Enders-Zohr P., Zhou Y., et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumour regression in patients with metastatic melanoma. J Immunother 22 (1999) 166-174
57. Vuylsteke R., Molenkamp B., Gietema H., et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 64 (2004) 8456-8460
58. Bell D., Chomarat P., Broyles D., et al. In breast carcinoma tissue, immature dendritic cells reside within the tumour, whereas mature dendritic cells are located in peritumoural areas. J Exp Med 190 (1999) 1417-1426
59. Heldin C., Rubin K., Pietras K., and Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4 (2004) 806-813
60. Chen Z., Malhotra P., Thomas G., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5 (1999) 1369-1379
61. Gattinoni L., Powell D., Rosenberg S., and Restifo N. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 (2006) 383-393
62. Ricci M., and Zong W. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11 (2006) 342-357
63. Hornef M., Wick M., Rhen M., and Normark S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 3 (2002) 1033-1040
64. Pulendran B., Smith J., Caspary G., et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 96 (1999) 1036-1041
65. Pulendram B., Banchereau J., Burkeholder S., et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 165 (2000) 566-572
66. Pinedo H., Buter J., Luykx-de Bakker S., et al. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer 39 (2003) 1061-1067
67. Nouri-Shirazi M., Banchereau J., Bell D., et al. Dendritic cells capture killed tumour cells and present their antigens to elicit tumour-specific immune responses. J Immunol 165 (2000) 3797-3803
68. Scaffidi P., Misteli T., and Bianchi M. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
69. Schmidt A., Yan S., Yan S., and Stern D. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (2001) 949-955
70. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2 (2002) 185-194
71. Somersan S., Larsson M., Fonteneau J., et al. Primary tumour tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 167 (2001) 4844-4852
72. Dengjel J., Schoor O., Fischer R., et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA 102 (2005) 7922-7927
73. Groh V., Li Y., Cioca D., et al. Efficient cross-priming of tumour antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumour cells. Proc Natl Acad Sci USA 102 (2005) 6461-6466
74. Ravetch J., and Bolland S. IgG Fc receptors. Annu Rev Immunol 19 (2001) 275-290
75. Kalergis A., and Ravetch J. Inducing tumour immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 195 (2002) 1653-1659
76. Ravetch J. A full complement of receptors in immune complex diseases. J Clin Invest 110 (2002) 1759-1761
77. Clynes R., Towers T., Presta L., and Ravetch J. Inhibitory Fc receptors modulate in vivo cytoxicity against tumour targets. Nat Med 6 (2000) 443-446
78. Boule M., Broughton C., Mackay F., et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199 (2004) 1631-1640
79. Magnusson M., Magnusson S., Vallin H., et al. Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol 54 (2001) 543-550
80. Molenkamp B., van Leeuwen P., van den Eertwegh A., et al. Immunomodulation of the melanoma sentinel lymph node: A novel adjuvant therapeutic option. Immunobiology 211 (2006) 651-661
81. Zhang L., Conejo-Garcia J., Katsaros D., et al. Intratumoural T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213